AUTHOR=Zhou Hui , Lai Kai-Fa , Xiang Qian , Xu Yu , Zhang Qian-Wen , Hu Cui , Mao Xi-Guang , Chen Cheng , Huang Wu , Mi Gong-Sheng , Shen Juan , Tian Yong , Ke Feng-Mei 

TITLE=Oncological Safety of Diagnostic Hysteroscopy for Apparent Early-Stage Type II Endometrial Cancer: A Multicenter Retrospective Cohort Study

JOURNAL=Frontiers in Oncology

VOLUME=Volume 12 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.918693

DOI=10.3389/fonc.2022.918693

ISSN=2234-943X

ABSTRACT=Objective
To compare the impact of methods of endometrial sampling on the prognosis of apparent early-stage type Ⅱ endometrial cancer.
Patients and Methods
A total of 429 women with presumed early-stage type Ⅱ endometrial cancer were included. The 5-year DFS and OS were estimated and compared using the Kaplan-Meier method and the log-rank test among patients diagnosed by Dilation & Curettage (D&C) or diagnostic hysteroscopy. The Cox proportional hazards regression model was employed to adjust for potential confounding factors.
Results
160 cases underwent D&C and 269 cases diagnosed by diagnostic hysteroscopy. The 5-year DFS rate was 72.17% in the hysteroscopy group and 76.16% in the D&C group, diagnostic hysteroscopy was not associated with deteriorated 5-year DFS (HR 1.25, 95% CI 0.84-1.86, P=0.281). The 5-year OS rate was 67.23% in the hysteroscopy group and 70.71% in the D&C group, diagnostic hysteroscopy did not increase the risk of all-cause death (HR 1.11, 95% CI 0.78-1.57, P=0.573). Multivariable analysis showed that the method of endometrial sampling was not independently associated with DFS (aHR 1.38, 95% CI 0.92-2.07, P=0.122) and OS (aHR 1.23, 95% CI 0.85-1.77, P=0.272).
Conclusion
For apparent early-stage type Ⅱ endometrial cancer, diagnostic hysteroscopy did not affect the oncological outcomes.